New CAR T Cell for Multiple Myeloma Approved by FDA

Ciltacabtagene autoleucel (cilta-cel) is indicated for patients with relapsed/refractory multiple myeloma who have already had many previous treatments.
FDA Approvals

source https://www.medscape.com/viewarticle/969380?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?